Background Despite enthusiasm on the role of repurposing in drug development, enhanced by the Covid-19 pandemic with the FDA granting emergency use authorization of several repurposed drugs to treat Covid-19, there remain knowledge gaps on why pharmaceutical companies abandon the development of promising drug candidates as well as facilitators and barriers to moving them back into development, a process often referred to as drug repurposing.

中文翻译：

---

为什么有前途的药物被搁置，重新利用它们的障碍和促进因素：系统文献综述

背景尽管 Covid-19 大流行使人们对重新利用在药物开发中的作用充满热情，并且 FDA 授予了几种重新利用的药物以治疗 Covid-19 的紧急使用授权，但在制药公司为何放弃开发有前景的药物方面仍然存在知识空白候选药物以及将它们重新投入开发的促进因素和障碍，这一过程通常被称为药物再利用。